Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-007: MK-2870 + Pembrolizumab vs Pembrolizumab in 1L Metastatic NSCLC
NCT06170788Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Dec 2023; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06170788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170788.